uniQure (QURE) Q2 FY26 earnings call

uniQure achieved significant regulatory clarity for its lead Huntington's disease program, AMT-130, with FDA alignment for an accelerated approval pathway BLA submission in Q3 FY26. The company also reported encouraging early clinical data for its epilepsy and Fabry disease programs, while maintaining a strong financial position with funding secured into 2030. Commercial preparations for AMT-130 are intensifying, focusing on treatment center readiness, community engagement, and market access.